Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.
Bleeding Disorder, Spleen Lesion, Liver Diseases
About this trial
This is an interventional prevention trial for Bleeding Disorder focused on measuring Biopsy, Cautery, Bleeding, Liver, Kidney, Spleen, Hemostasis
Eligibility Criteria
Inclusion Criteria: Patients referred to interventional radiology for clinically indicated liver, kidney, or spleen biopsy for diffuse or focal disease, who also have one or more of the following risk factors for bleeding: Coagulopathy (INR ≥ 1.5) or thrombocytopenia (platelets < 50) before correction Renal disease with glomerular filtration rate (GFR) < 30 ml/min Liver cirrhosis Anticoagulant or antiplatelet medications where periprocedural withholding poses Competing medical risk, or the urgency of the procedure precludes holding the anticoagulant medications for the standard interval (departmental guidelines). Any splenic biopsy Hypervascular masses in the liver or kidney Renal and liver parenchymal biopsies, which are known to carry a higher risk of bleeding. Exclusion Criteria: Uncorrectable coagulopathy (INR remaining ≥ 2.5) or thrombocytopenia (platelets remaining < 25) Pregnancy Patients who are not competent to provide their own consent
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Experimental
RF biopsy track cautery
This study is designed as an open-label, single arm study, wherein all study participants will undergo RF track cautery during percutaneous liver, kidney, or spleen biopsy.